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Research Article
Introduction
The serine protease tissue plasminoNR1gen activator (tPA) is one
of two mammalian proteases that convert plasminogen into active
plasmin, leading to fibrin degradation (Vassalli et al., 1991). This
has been the rationale for the development of a recombinant form
of tPA (Actilyse®), which remains to date the only approved drug
for the acute treatment of ischemic stroke (1995). Unfortunately,
the achievable benefit of tPA-induced thrombolysis is limited by a
narrow therapeutic window (Hacke et al., 2008) and a risk of
hemorrhagic transformation (The National Institute of Neurological
Disorders and Stroke rt-PA Stroke Study Group, 1995; Saqqur et
al., 2008). Concordant experimental data also suggests that tPA
(endogenous and exogenous) might endanger endothelial and
neuronal cells, leading to an alteration of the integrity of
components of the neurovascular unit (for a review, see Yepes et
al., 2009). Moreover, intravenously injected tPA can cross the
intact or damaged blood–brain barrier (BBB) and thus promote
excitotoxic brain damage in rodents (Benchenane et al., 2005a;
Lopez-Atalaya et al., 2007).
Since the pioneering work of Tsirka and colleagues (Tsirka et
al., 1995), which demonstrated that endogenous tPA has a role in
aggravation upon excitotoxic neuronal death, several plasminogen-
dependent and -independent mechanisms have been proposed to
explain the deleterious effects of this protease in the ischemic brain
(for a review, see Samson and Medcalf, 2006; Wang et al., 2008;
Yepes et al., 2009). We (Benchenane et al., 2007; Fernandez-
Monreal et al., 2004; Nicole et al., 2001) and others (Kvajo et al.,
2004; Samson et al., 2008) have proposed that tPA is able to cleave
the GluN1 subunit of the glutamatergic N-methyl-D-aspartate
(NMDA) receptors, either directly (Nicole et al., 2001) and/or
through cooperation with a third partner (Samson et al., 2008).
This proteolysis occurs on the extracellular amino-terminal domain
(ATD) of GluN1 and leads to an increase in Ca2+ influx through
activated NMDA receptors to potentially toxic levels (Fernandez-
Monreal et al., 2004; Nicole et al., 2001). More recently, we have
proposed a 3D model of this interaction of tPA with the NMDA
receptor GluN1 subunit, which occurs by a two-site ‘docking
system’, in which the binding of the lysine binding site (LBS) of
the Kringle-2 domain of tPA to one unit of a GluN1 dimer is the
crucial step for subsequent proteolysis (Lopez-Atalaya et al., 2008).
Together, these observations highlight the multifaceted aspects of
tPA in an ischemic context, with both beneficial and deleterious
effects, depending on the compartment, the timing and the target
protein.
High mobility group box-1 protein (HMGB-1), which is also
called amphoterin, is a non-histone DNA binding protein composed
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of a C-terminal tail and two HMG boxes (A and B) that are DNA
binding domains (Landsman and Bustin, 1993). First described as
a chromosomal protein, HMGB-1 has been implicated in diverse
intracellular functions including the stabilization of nucleosomal
structure and the facilitation of gene transcription (Bustin, 1999).
In addition, HMGB-1 was described as a cytokine-like mediator of
delayed endotoxin lethality and inflammation (Abraham et al.,
2000; Bonaldi et al., 2003; Wang et al., 1999). In the brain, HMGB-
1 is synthesized by neurons and astrocytes and has been reported
to be released after cytokine stimulation and to elicit inflammatory
processes (Agnello et al., 2002; Wang et al., 1999). However,
because HMGB-1, through its LBS, has been reported to bind both
tPA and plasminogen, resulting in an increased transformation of
plasminogen into active plasmin (Parkkinen and Rauvala, 1991),
we postulated that HMGB-1 could be an interesting modulator of
the effects of tPA during ischemic stroke.
In this study, we demonstrate in vitro that by interacting with
tPA, HMGB-1 can reverse the side effects of tPA, including its
ability to cross the BBB and to promote BBB leakage and neuronal
death, while concurrently promoting the beneficial fibrinolytic
activity of tPA. Thus, although HMGB-1 is known to promote
inflammatory processes following stroke (Hayakawa et al., 2008;
Kim et al., 2006; Liu et al., 2007; Qiu et al., 2008; Qiu et al.,
2010), our work provides evidence that HMGB-1 can counteract
the deleterious effects of tPA and therefore should be considered
as a new therapeutic strategy for stroke.
Results
HMGB-1 increases tPA-mediated plasmin formation and
blood clot lysis
We first investigated the influence of recombinant HMGB-1 on the
ability of recombinant tPA to convert plasminogen into active
plasmin. When compared with tPA alone (0.5 M), tPA and
recombinant HMGB-1 together led to a dose-dependent increase
in plasmin formation (+30%, +62% and +130% at 1, 2 and 4 M
HMGB-1 respectively; P<0.01; n6) (Fig. 1A). Addition of
HMGB-1 alone did not promote plasmin formation (data not
shown). Accordingly, in an in vitro human plasma clot lysis assay,
tPA alone induced clot lysis in a dose-dependent manner, an effect
promoted by the addition of recombinant HMGB-1 (Fig. 1B).
Interestingly, addition of equimolar HMGB-1 to the lowest dose of
tPA tested (15 nM) resulted in a similar efficiency of clot lysis as
the highest dose of tPA alone (75 nM; n3, P<0.05) (Fig. 1B).
Thus, as previously suggested (Parkkinen and Rauvala, 1991), we
show that HMGB-1 can promote tPA-dependent fibrinolysis.
HMGB-1 decreases the passage of tPA through the BBB
In accordance with previous observations (Benchenane et al.,
2005a; Benchenane et al., 2005b), we confirm by using an in vitro
model of the BBB (Fig. 2A), that tPA can cross the BBB under
normal conditions and that this passage is increased under ischemic-
like conditions (oxygen and glucose deprivation, OGD). Under
control conditions, HMGB-1 (0.3 M) significantly reduced the
passage of tPA (–30%, P<0.05, n3) from the luminal (‘vascular’)
to the abluminal (‘parenchymal’) compartment, as demonstrated
by zymography and its corresponding densitometric analyses (Fig.
2B). None of these conditions altered the permeability of the BBB
(Fig. 2D, control conditions). Under OGD conditions, the passage
of tPA alone was dramatically increased (+482% compared with
tPA alone in control conditions P<0.05, n3), yet in the presence
of HMGB-1, this passage was significantly decreased (–20% versus
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the passage of tPA alone under OGD conditions, P<0.05, n3)
(Fig. 2C). tPA aggravated OGD-induced BBB permeabilization
(passage of Lucifer Yellow increased by 132% P<0.001, n6; Fig.
2D), but this alteration of BBB integrity was partially prevented by
the co-administration of HMGB-1 (–58% versus tPA alone,
P<0.001, n6; Fig. 2D).
HMGB-1 reverses the pro-neurotoxic effect of tPA
To determine whether HMGB-1 could influence the ability of tPA
to promote NMDA-induced neuronal death, we used a model of
excitotoxicity induced by exposure of primary cortical neuronal
cultures to NMDA (10 M, 24 hours). Whereas NMDA produced
acute cell body swelling, followed 24 hours later by neuronal
degeneration (30%), as measured by the release of lactate
dehydrogenase in the bathing medium, neither tPA (0.3 M) nor
HMGB-1 (0.3 M) alone induced neuronal death. However,
although tPA caused a twofold increase in NMDA-induced neuronal
death (n10, *P<0.05), co-application of HMGB-1 prevented the
pro-excitotoxic effects of tPA on NMDA-induced neuronal death
(Fig. 3A).
It was previously demonstrated that tPA increases excitotoxicity
by interacting with, and cleaving the ATD-GluN1 subunit of NMDA
receptors (Benchenane et al., 2007; Nicole et al., 2001). Here, we
performed immunoblots after incubation of the recombinant form
of ATD-GluN1, with tPA and/or HMGB1. We observed that after
Fig. 1. Effects of tPA and HMGB-1 on plasminogen to plasmin conversion
and clot lysis. (A)Plasmin formation was measured with a specific
chromogenic substrate in the presence of tPA (0.5M) and HMGB-1 at
different concentrations (0 to 4M) (n six per group). *P<0.05, **P<0.01
compared with tPA 0.5M. (B)Effect of tPA (15 or 75 nM) alone or together
with HMGB-1 (7.5, 15 and 30 nM) on human clot lysis performed by
measuring fluorescence released from a pre-formed clot as described in the
methods section (n six per group). *P<0.05.
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tPA treatment, recombinant ATD-GluN1 was cleaved, whereas this
peptide remained unaffected after the co-application of
tPA+HMGB-1 (Fig. 3B) (n3). Using pull-down assays performed
with antibodies directed against either HMGB-1 or GluN1, we
observed no evidence that HMGB-1 complexes with GluN1 (Fig.
3C), thus ruling out the possibility that the prevention of ATD-
GluN1 cleavage by tPA in the presence of HMGB-1 was due to a
competition for the binding to ATD-GluN1.
HMGB-1 prevents tPA from potentiating NMDA-evoked
Ca2+ influx
We then investigated whether the effects observed in the excitotoxic
neuronal death paradigm were correlated with a modulation of
NMDA-evoked Ca2+ influx, which is one of the crucial events in
excitotoxic necrosis. By using Fura-2 fluorescence videomicroscopy
(Fig. 4A,B), we found that tPA (0.3 M for 15 minutes) increased
NMDA-induced Ca2+ influx in cultured cortical neurons by
approximately 45%, whereas the co-application of tPA and HMGB-
1 (0.3 M each for 15 minutes) prevented the potentiation of Ca2+
influx in neurons (n5 independent experiments for a total of 140
cells per condition). This was not due to an effect of HMGB-1 by
itself, because it did not alter the extent of NMDA-evoked Ca2+
responses (data not shown). These results are in agreement with
the observation that HMGB-1 prevents both the cleavage of ATD-
GluN1 and the pro-excitotoxic effects induced by tPA.
Discussion
In addition to its nuclear functions (for a review, see Bustin, 1999),
HMGB-1 is reported to act as a pro-inflammatory cytokine or
mediator (Rouhiainen et al., 2007; Wang et al., 1999) and was thus
considered as a deleterious molecule in experimental models of
cerebral ischemia (Kim et al., 2006; Liu et al., 2007; Muhammad
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et al., 2008). However, stroke pathogenesis is complex, involving
not only local and peripheral inflammatory events, but also a set
of cascades that challenge the integrity and survival of all
components of the neurovascular unit (for a review, see Dirnagl et
al., 1999). The first emergency treatment of ischemic stroke is to
restore cerebral blood flow, with tPA-induced reperfusion being
the only approved treatment (The National Institute of Neurological
Disorders and Stroke rt-PA Stroke Study Group, 1995).
Nevertheless, it is now well known that tPA is a multifaceted
molecule, displaying both beneficial (thrombolytic activity in the
vascular compartment) and deleterious effects (promotion of BBB
leakage, hemorrhagic transformation, and neuronal and endothelial
cell death) (for a review, see Yepes et al., 2009). The positive and
negative effects concern both endogenously produced and
intravenously administered tPA, which has also been shown to
cross the BBB, even when BBB integrity is not compromised
(Benchenane et al., 2005a; Benchenane et al., 2005b). Here, in a
set of well-characterized in vitro models, we show that in the
presence of HMGB-1, the fibrinolytic activity of tPA is significantly
increased, whereas its ability to cross the BBB and to promote
BBB leakage and excitotoxicity are significantly reduced.
The rationale for the use of tPA for acute ischemic stroke
treatment, relies on its ability to convert plasminogen into active
plasmin, the trypsin-like serine protease driving the enzymatic
dissolution of fibrin clots. As a result of its high affinity for fibrin,
tPA activates clot-bound plasminogen 100-times more efficiently
than it does circulating plasminogen (Tanswell et al., 1989).
However, considering the high dose of tPA administered for
thrombolysis in stroke patients (0.9 mg per kg of body weight;
10% given as a bolus followed by constant infusion of the
remaining 90% over 1 hour), one can estimate that a significant
proportion of the protease can exert effects other than the expected
Fig. 2. HMGB-1 reduces the passage of tPA
across the BBB in vitro in both control and
OGD conditions. (A)tPA alone (0.3M) or in
the presence of HMGB-1 (0.3M) was applied
on the upper endothelial compartment. (B,C)tPA
activity was measured after 2 hours in the lower
medium by zymography assay both in control and
OGD conditions. Densitometries are normalized
to rtPA (mean values ± s.e.m. of three experiments
per group; *P<0.05 Mann–Whitney test). In both
control and OGD, HMGB-1 decreases passage of
tPA through the BBB. (D)BBB permeability to
Lucifer Yellow (Pe) was not modified by tPA
and/or HMGB-1 in control conditions. OGD by
itself increases Pe compared with normoxia and is
potentiated by tPA. HMGB-1 does not change Pe
under OGD conditions but prevents tPA
increasing Pe. Results are presented as mean ±
s.e.m. The 100% control value represents a Pe of
0.4010–3 cm/minute for LY after 4 hours under
control conditions without treatment. The mean
scores were significant using one-way ANOVA
(***P<0.001; n six monolayers per treatment,
Bonferroni’s test).
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thrombolysis, such as bleeding. Accordingly, it might be crucial to
reduce the doses of tPA to limit these side effects and in this view,
our finding that HMGB-1 potentiates the ability of tPA to convert
plasminogen into plasmin, and thus promotes clot lysis, opens an
interesting area of investigation.
We have previously demonstrated both in vitro and in vivo, that
exogenous tPA crosses the intact BBB through a low-density-
lipoprotein-related receptor protein (LRP)-dependent transcytosis
and thus promotes excitotoxic neuronal death (Benchenane et al.,
2005a; Benchenane et al., 2005b). In addition, following OGD, a
condition known to mimic in vitro the ischemic condition at the
stage of occlusion, which induces an early increase of BBB
permeability (Brillault et al., 2002; Mysiorek et al., 2009), we
demonstrated that the transport of tPA across the BBB was
dramatically increased and that the mechanism of passage shifted
from an LRP-dependent process to an LRP-independent one
(Benchenane et al., 2005b). The interaction of tPA with LRP at the
parenchymal level of the neurovascular unit has also been
associated with edema formation and activation of metalloproteases,
including MMP-9, in addition to subsequent hemorrhagic
transformation (for a review, see Yepes et al., 2009). Here, we
observed that HMGB-1 significantly decreases the passage of tPA
across our model of BBB (under normal or ischemic-like
conditions). Because HMGB-1 alone did not reduce OGD-induced
BBB leakage, our study suggests that by physically interacting
with tPA, HMGB-1 prevents LRP-dependent and -independent
passages of tPA, thus indirectly protecting the BBB. This suggests
that an adjunct therapy coupling HMGB-1 to tPA might reduce the
extent of BBB leakage and edema in stroke patients.
Previously, HMGB-1 has been shown to increase neuronal death
induced by exposing mixed cultures of neurons and glial cells to
low doses of glutamate, whereas HMGB-1 had no effect in high
doses of glutamate (Faraco et al., 2007). The glutamate dose-
dependent effect of HMGB-1 was not reversed by addition of an
anti-inflammatory agent, suggesting a role for HMGB-1 in
glutamate-mediated neurotoxicity. In our model of primary cultures
of pure cortical neurons, HMGB-1 did not influence NMDA-
mediated neurotoxicity (Fig. 3A), but specifically protected neurons
2073HMGB-1 decreases tPA-mediated neurotoxicity
from the pro-excitotoxic effects of tPA (Benchenane et al., 2007;
Nicole et al., 2001). This neuroprotection results from the
prevention of the physical interaction between tPA and the NMDA
receptor subunit GluN1, an interaction that otherwise results in
increased Ca2+ influx through activated NMDA receptors (Nicole
et al., 2001; Samson et al., 2008). Our recent demonstration that
the deleterious effect of tPA on NMDA-receptor-mediated neuronal
loss is dependent on its kringle-2 domain (Lopez-Atalaya et al.,
2008), together with the demonstration that HMGB-1 interacts
with the lysine binding sites within the kringle-2 domain of tPA
(Parkkinen and Rauvala, 1991), suggest that HMGB-1 protects
neurons by occupying the site of interaction of tPA with the GluN1
subunit.
Altogether, our in vitro data suggest that HMGB-1 can
potentially exert several beneficial effects during stroke: a
potentiation of tPA-dependent fibrinolysis and the blockage of
tPA-dependent parenchymal side effects. However, HMGB-1 has
been reported to promote expression of pro-inflammatory cytokines
such as TNF (Rouhiainen et al., 2007), and inflammation is
currently considered to be a deleterious pathway in a stroke context.
Accordingly, it was demonstrated, in vivo, that HMGB-1 could
promote delayed inflammatory processes in the post-ischemic
brain, with global deleterious effects (Kim et al., 2006).
Surprisingly, in this work, the authors performed injections of
short hairpin RNA against HMGB-1 into the striatum, despite
reporting decreased levels of HMGB-1 due to ischemia. Yet, their
conclusions were that HMGB-1 aggravates ischemic damage to
the brain by promoting late inflammatory processes. In another
study, Liu and colleagues demonstrated in rats that a monoclonal
antibody against the acidic tail of HMGB-1 led to a 90% reduction
in infarct size after the occlusion of the middle cerebral artery,
which resulted in an overall improvement of the neurological
outcome (Liu et al., 2007). The antibody was injected intravenously
immediately or 6 hours after the initiation of mechanical
reperfusion. The authors correlated the reduction in infarct size
with a decrease in inflammatory markers and activation of
metalloproteinases such as MMP-9 (Liu et al., 2007). Similar
conclusions were reported when this antibody was used in a model
Fig. 3. Effect of tPA–HMGB-1 complexes on neurotoxicity mediated by tPA. (A)Neuronal death was quantified by measuring LDH release into the medium
after a 24 hour exposure to NMDA (10M) in the presence or absence of tPA (0.3M) and HMGB-1 (0.3M). The co-application of HMGB-1 counteracts the
pro-excitotoxic effects of tPA (n16, *P<0.05). (B)HMGB-1 prevents tPA from cleaving the recombinant form of the N-terminal domain of the NMDA receptor
subunit (ATD-GluN1) (three independent assays). (C)The prevention of tPA-mediated cleavage of the ATD-GluN1 is not due to an interaction between tPA and
NMDA receptor as shown by immunoprecipitation experiments using antibodies against GluN1 or HMGB-1. IP, immunoprecipitation; IB, immunoblot.
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of focal permanent ischemia (Muhammad et al., 2008). Of note,
none of these studies investigated tPA-mediated thrombolysis, a
major parameter with regard to the clinical setting (Kim et al.,
2006; Liu et al., 2007; Muhammad et al., 2008). In our study, we
show the role of HMGB-1 as a catalyst for tPA-driven thrombolysis.
Despite the apparent contradiction with these in vivo studies
(mainly suggesting delayed pro-inflammatory effects in the
vasculature), our in vitro findings suggest that HMGB-1 can exert
beneficial effects during ischemic stroke (by preventing BBB
leakage, increasing clot dissolution and reducing excitotoxic
neuronal loss). Interestingly, it was previously demonstrated that
HMGB-1 binds to tPA through its Box-A domain (Parkkinen and
Rauvala, 1991), suggesting that the C-tail, which is known to
mediate the inflammatory effects of HMGB-1 (Liu et al., 2007;
Muhammad et al., 2008; Rouhiainen et al., 2007; Sha et al., 2008;
Tian et al., 2007), might not be necessary for the beneficial effects
of HMGB-1. However, the recent demonstration that inflammatory
cytokines, such as IL-1, can contaminate the purified product
during some HMGB-1 purification processes, adds a note of caution
to the interpretation of some data (Sha et al., 2008). In a recent
review, it has been suggested that HMGB-1 could have biphasic
actions during stroke: an early and noxious inflammatory effect,
but delayed beneficial actions, including stem cell migration into
the ischemic region, and promotion of neurogenesis, vasculogenesis
and angiogenesis (Hayakawa et al., 2010a; Hayakawa et al., 2010b).
Here, our results implement this work, by demonstrating the pro-
thrombolytic and protective effect of HMGB-1 for the BBB and
neurons.
Overall, the literature argues against the direct use of HMGB-1
because of pro-inflammatory properties. However, we provide
evidence here suggesting that injection of HMGB-1 into the
circulation might concurrently promote tPA-dependent fibrinolytic
activity and prevent its passage across the BBB. Moreover, if vascular
2074 Journal of Cell Science 124 (12)
HMGB-1 can cross the BBB, its injection could help to prevent the
pro-neurotoxic effects of tPA. However, a clear demonstration of the
passage of HMGB-1 remains to be established because conflicting
results have been reported (Kim et al., 2006; Muhammad et al.,
2008; Qiu et al., 2008). In addition, the impermeability to HMGB-
1 of the insert used in our in vitro model of BBB did not allow us
to investigate this question (data not shown). Despite this, endogenous
HMGB-1 released in the brain parenchyma might at least prevent
the pro-neurotoxic effects of tPA, as well as its damaging effect on
the BBB. Development of HMGB-1-derived molecules devoid of
inflammatory actions could be an alternative safer strategy. In line
with this hypothesis, it has been shown in a stroke model that Box-
A of HMGB-1 prevents the binding of HMGB-1 to RAGE (receptor
for advanced glycation end products), leading to a decrease in infarct
volume (Muhammad et al., 2008). Understanding which part(s) of
the HMGB-1 molecule is involved in each of these processes is thus
mandatory to the development of a more effective therapy for the
treatment of stroke.
Materials and Methods
Reagents
tPA was purchased from Boehringer Ingelheim. Recombinant HMGB-1 was produced
and purified as described previously (Parkkinen and Rauvala, 1991). Briefly, HMGB-
1 was produced in a baculovirus system on a 5 ml heparin-Sepharose Hi-Trap-
column (Pharmacia). The column was eluted with a linear gradient of 0.15–1.5 M
NaCl in 50 mM Tris-HC1, pH 8.5. Fractions containing recombinant HMGB-1 were
pooled and subjected to a second round of purification on heparin-Sepharose under
the same conditions.
Cell culture
Primary cultures of cortical neurons were prepared from fetal mice (E15-E16).
Dissociated cortical cells were resuspended in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum, 5% horse serum, and 1 mM
glutamine, and plated in 24-well dishes previously coated with poly-D-lysine and
laminin. After 3 days in vitro (DIV), the cells were exposed to 10 M Ara-C to
inhibit glial proliferation. Cultures were used after 14 DIV for excitotoxicity and
Ca2+ assays.
Fig. 4. HMGB-1 prevents tPA-promoted NMDA-
induced neuronal Ca2+ influx. (A)Three successive 30
second exposures (N) to NMDA (10M) led to a rapid and
reproducible Ca2+ influx in cultured cortical neurons (n3).
Cells were then incubated for 15 minutes with tPA alone or
with HMGB-1 and NMDA exposure performed again.
(B)In contrast to tPA alone (0.3M), when co-incubated
with HMGB-1 (0.3M), tPA does not promote NMDA-
induced Ca2+ influx in neurons. *P<0.05 compared with
control exposure with NMDA only; tested by ANOVA for
repeated measures followed by a Bonferroni–Dunn’s test
for multiple comparisons.
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Excitotoxicity
Slowly triggered excitotoxicity was induced at 37°C by a 24 hour exposure to 10
M NMDA in DMEM supplemented with glycine (10 M). Neuronal death was
estimated by phase-contrast microscopy and quantified by measurement of lactate
dehydrogenase (LDH) release by damaged cells into the bathing medium. The LDH
level corresponding to complete neuronal death was determined in sister cultures
exposed to 200 M NMDA for 24 hours in DMEM supplemented with glycine.
Background LDH levels were determined in sister cultures subjected to sham wash
and subtracted from experimental values to yield the signal specific to experimentally
induced injury.
Measurement of tPA-dependent conversion of plasminogen into plasmin
tPA (2 g/ml) was incubated for 1 hour at 22°C in fibrin-coated microtitre plates
followed by three PBS washes to remove non-fixed tPA. Plasminogen (0.3 M)
alone, or in combination with increasing concentrations of HMGB1 (0.5 to 4 M),
were added. The kinetics of plasmin formation was followed for 2 hours by measuring
the release of para-nitroaniline from the plasmin sensitive chromogenic substrate
CBS0065 (0.75 mM; Diagnostica Stago, France) by measuring its absorbance at 405
nm.
In vitro human clot lysis
A pool of human plasma was given by l’Etablissement Français du Sang. 500 l of
human plasma, 20 mM CaCl2, and 0.1 mg/ml fibrinogen labeled with Alexa Fluor
647 (Molecular Probes) were combined. Human thrombin (Sigma, France) at 1
NIHU/ml was added to promote coagulation. Plasma solutions were incubated for 2
hour at 37°C to promote clot formation. For clot lysis, 2 ml of human plasma
containing tPA and/or HMGB-1 at varying concentrations were added, and
fluorescence activity measured every hour by measuring free Alexa Fluor 647
(InVitrogen, France) released into the supernatant.
Immunoblotting
Lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100) containing
protease and phosphatase inhibitor cocktails (1:100, Sigma) and PMSF (1 mM), was
used to solubilize cell lysates. Supernatants were harvested after centrifugation at
9000 g for 10 minutes and protein concentrations were estimated with the BCA
assay (Pierce, Rockford, IL). Protein samples were separated by SDS-PAGE and
transferred onto a PVDF membrane. Membranes were blocked for 2 hours in 5%
dried milk and Tris-buffered saline containing 0.1% Tween-20 and incubated
overnight at 4°C with the primary antibody (Amphoterin, 1:3000; Sigma).
Biotinylated secondary antibody (1:10,000) was added for 1 hour followed by
incubation at room temperature with peroxidase-conjugated streptavidin (1:2500) for
1 hour. Proteins were detected with a chemiluminescence ECL Plus immunoblotting
detection system (Perkin Elmer-NEN, Paris, France).
Ca2+ videomicroscopy analysis
Primary cultures (14 DIV) of cortical neurons were loaded in the presence of a
HEPES-buffered saline solution containing 5 M Fura-2/AM and 0.1% pluronic F-
127 (Molecular Probes, Leiden, The Netherlands) (45 minutes, 37°C). Experiments
were performed at 22°C on a Nikon Eclipse inverted microscope equipped with a 75W
Xenon lamp and a Nikon 40, 1.3 numerical aperture epifluorescence oil-immersion
objective. Fura-2 (excitation: 340, 380 nm, emission: 510 nm) ratio images were
acquired with a CCD camera (Princeton Instrument, Trenton, NJ), and digitized
(256512) using Metafluor 4.11 software (Universal Imaging Corporation, Cherter,
PA).
Construction of His-tagged recombinant ATD-GluN1 domain
The region of the GluN1 subunit encoding amino acids 19–371 of GluN1-1a
corresponding to the ATD was amplified from the full-length rat GluN1-1a cDNA
by the upstream primer 5-cgggatcccgcgccgcctgcgac-3 (generating a BamHI
restriction site) and the downstream primer 5-atgggtaccattgtagatgcccac-3 (containing
an internal KpnI restriction site). PCR products were digested and inserted into the
pQE100-Double Tag vector (Qiagen, Courtaboeuf, France) which encodes 6His at
the N-terminus of the insert. Recombinant proteins were purified from inclusion
bodies of IPTG-induced bacterial cultures (E.coli, M15 strain) on a nickel affinity
matrix as described by the manufacturer (Qiagen, Courtaboeuf, France) and analysed
either by silver or Coomassie Blue staining after SDS-PAGE.
Immunoprecipitation
Recombinant proteins were incubated at 4°C for 1 hour before immunoprecipitation.
Proteins were incubated with ATD antibody for 2 hours at 4°C (1/1000 Penta-His,
Qiagen, France) followed by adsorption to protein G-Sepharose (Amersham, France).
Bound proteins were eluted in DTT and -mercaptoethanol sample buffer and
separated with SDS-PAGE electrophoresis.
Zymography assays
Zymography was performed by adding plasminogen (4.5 g/ml) and casein (5 mg)
to a 12.6% SDS-PAGE. Electrophoresis was performed at 4°C and gels were washed
with Triton X-100 (2.5%) and incubated at 37°C. Caseinolytic bands were visualized
with Coomassie Blue staining.
In vitro model of BBB
The method of Dehouck and colleagues (Dehouck et al., 1990) was used with minor
modifications. Bovine brain endothelial cells isolated from capillary fragments were
co-cultured with primary mixed glial cells from newborn Sprague–Dawley rats. The
glial cells were isolated and cultured for 3 weeks, plated on the bottom of cell culture
clusters containing six wells each. The endothelial cells were seeded onto cell culture
inserts, which were placed in the wells containing glial cells. The medium used for
the co-culture was DMEM supplemented with 10% calf serum, 10% horse serum, 2
mM glutamine, 50 mg/l gentamicin, and 1 g/l basic fibroblast growth factor
(Sigma). The medium was changed every 2 days and under these conditions,
endothelial cells formed a confluent monolayer after 7 days. Experiments were
performed 5 days after confluency.
Transport studies in control conditions
Permeability studies were performed using Lucifer Yellow (LY) (Lucifer Yellow CH
dilithium, Sigma), recombinant HMGB-1, or recombinant tPA. LY is a non-
radioactive surrogate marker of BBB integrity, with a good correlation with other
markers such as sucrose permeability and integrity of tight junction proteins (Culot
et al., 2009; Mysiorek et al., 2009). In these studies, endothelial cell monolayers
were transferred to six-well plates containing 2.5 ml Ringer–HEPES solution (150
mM NaCl, 5.2 mM KCl, 2.2 mM CaCl2, 0.2 mM MgCl2(6H2O), 6 mM NaHCO3, 5
mM HEPES, 2.8 mM glucose, pH 7.4) per well. 1.5 ml Ringer–HEPES solution
containing LY at 50 M and 20 mg/l tPA (only for tPA transport). Incubations were
performed at 37°C. At 20, 40 and 60 minutes (for LY), or after 2 hours for tPA and
HMGB-1, an aliquot from each lower compartment and stock solution was taken.
Quantification of fluorescence was performed with an aliquot of 200 l withdrawn
from each abluminal compartment at each time and 20 l of luminal compartment
and initial solution (Fluoroskan Ascent FL Thermolabsystems). tPA activity in the
abluminal compartment was determined by zymography as previously described.
For LY, triplicate control wells were also assayed to determine the endothelial
permeability coefficient (Pe) calculated in centimeters per minute as previously
described (Dehouck et al., 1992). In this calculation, both filter permeability
(Psfinsert filter + collagen coating) and filter plus cell permeability (Pstfilter +
collagen + endothelial cells) were taken into account, according to the formula:
1/Pe1/Pst–1/Psf.
For each experimental condition, data were mean values ± s.e.m. (n6 experiments)
of LY Pe (in cm/minute) passage through the endothelial monolayer. All transport
data were expressed as a percentage of the control.
Transport studies during OGD
OGD transport studies were performed as described above. DMEM and Ringer–
HEPES solutions were first equilibrated with nitrogen and glucose was removed
from the medium (Brillault et al., 2002). Cells were incubated in Gas Pack EZ bags
(Becton Dickinson, Sparks, MD) for the indicated time and transport studies were
performed in an airtight glove box filled with nitrogen at 37°C (Forma Scientific,
Mountain View, CA).
Statistical analysis
Results are expressed as the mean ± s.e.m. Statistical analyses were performed by a
Kruskal–Wallis test followed by a Mann–Whitney test, and Bonferroni test for LY
permeability studies.
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